Immune response, diagnosis and treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis lung disease

Current Pharmaceutical Design

Volumn 19, Issue 20, 2013, Pages 3669-3678

  Eickmeier, Olaf ^a   Rieber, Nikolaus ^b   Eckrich, Jonas ^a   Hector, Andreas ^b   Graeppler Mainka, Ute ^b   Hartl, Dominik ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Allergic Bronchopulmonary Aspergillosis (ABPA); Cystic fibrosis; Immune response

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; BUDESONIDE; COLECALCIFEROL; FLUCONAZOLE; FLUTICASONE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 13; INTERLEUKIN 25; INTERLEUKIN 4; INTERLEUKIN 5; ITRACONAZOLE; METHYLPREDNISOLONE; OMALIZUMAB; PLACEBO; POSACONAZOLE; PREDNISONE; STEROID; THYMIC STROMAL LYMPHOPOIETIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRIAZOLE; VORICONAZOLE;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ALTERNARIA; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; ATYPICAL MYCOBACTERIUM; BASOPHIL; BURKHOLDERIA CEPACIA; CANDIDA; CELL ACTIVATION; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE SEVERITY; FLUSHING; GENETIC POLYMORPHISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN BLOOD LEVEL; LUNG FIBROSIS; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG MYCOSIS; MALAISE; MYALGIA; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESTLESSNESS; REVIEW; SCEDOSPORIUM APIOSPERMUM; SIDE EFFECT; STENOTROPHOMONAS MALTOPHILIA; SYSTEMIC MYCOSIS;

ANIMALS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; CHRONIC DISEASE; CYSTIC FIBROSIS; HUMANS; PHENOTYPE;

EID: 84878668026     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990349     Document Type: Review

References (132)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352(19): 1992-2001.
2. Anderson MP, Gregory RJ, Thompson S, et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 1991; 253(5016): 202-5.
3. Brennan S. Innate immune activation and cystic fibrosis. Paediatr Respir Rev 2008; 9(4): 271-9; quiz 9-80.
4. Eickmeier O, Huebner M, Herrmann E, et al. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine 2010; 50(2): 152-7.
5. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151(4): 1075-82.
6. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152(6 Pt 1): 2111-8.
7. Konstan MW, Walenga RW, Hilliard KA, Hilliard JB. Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 1993; 148(4 Pt 1): 896-901.
8. Hartl D, Latzin P, Hordijk P, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007; 13(12): 1423-30.
9. Doring G. Eradication of Pseudomonas aeruginosa by early antibiotic treatment has been one of the major advances in the last decade for subjects with CF. Introduction. J Cyst Fibros 2012; 11(1): 1.
10. Skov M, McKay K, Koch C, Cooper PJ. Prevalence of allergic bronchopulmonary aspergillosis in cystic fibrosis in an area with a high frequency of atopy. Respir Med 2005; 99(7): 887-93.
11. Bargon J, Dauletbaev N, Kohler B, Wolf M, Posselt HG, Wagner TO. Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients. Respir Med 1999; 93(11): 835-8.
12. Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179(5): 1190-6.
13. Chotirmall SH, Branagan P, Gunaratnam C, McElvaney NG. Aspergillus/ allergic bronchopulmonary aspergillosis in an Irish cystic fibrosis population: a diagnostically challenging entity. Respir Care 2008; 53(8): 1035-41.
14. Speirs JJ, van der Ent CK, Beekman JM. Effects of Aspergillus fumigatus colonization on lung function in cystic fibrosis. Curr Opin Pulm Med 2012; 18(6): 632-8.
15. Chotirmall SH, Greene CM, McElvaney NG. Candida species in cystic fibrosis: A road less travelled. Med Mycol 2010; 48 Suppl 1: S114-24.
16. Hinson KF, Moon AJ, Plummer NS. Broncho-pulmonary aspergillosis; a review and a report of eight new cases. Thorax 1952; 7(4): 317-33.
17. Amin R, Dupuis A, Aaron SD, Ratjen F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 2010; 137(1): 171-6.
18. Wojnarowski C, Eichler I, Gartner C, et al. Sensitization to Aspergillus fumigatus and lung function in children with cystic fibrosis. Am J Respir Crit Care Med 1997; 155(6): 1902-7.
19. Nicolai T, Arleth S, Spaeth A, Bertele-Harms RM, Harms HK. Correlation of IgE antibody titer to Aspergillus fumigatus with decreased lung function in cystic fibrosis. Pediatr Pulmonol 1990; 8(1): 12-5.
20. de Vrankrijker AM, van der Ent CK, van Berkhout FT, et al. Aspergillus fumigatus colonization in cystic fibrosis: implications for lung function? Clin Microbiol Infect 2011; 17(9): 1381-6.
21. Milla CE, Wielinski CL, Regelmann WE. Clinical significance of the recovery of Aspergillus species from the respiratory secretions of cystic fibrosis patients. Pediatr Pulmonol 1996; 21(1): 6-10.
22. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110(5): 685-92.
23. Ben-Ami R, Lewis RE, Kontoyiannis DP. Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. Br J Haematol 201; 150(4): 406-17.
24. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12(2): 310-50.
25. Agarwal R. Severe asthma with fungal sensitization. Curr Allergy Asthma Rep 2011; 11(5): 403-13.
26. Hogan C, Denning DW. Allergic bronchopulmonary aspergillosis and related allergic syndromes. Semin Respir Crit Care Med 2011; 32(6): 682-92.
27. Knutsen AP, Bush RK, Demain JG, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol 2012; 129(2): 280-91; quiz 92-3.
28. Romani L, Zelante T, De Luca A, et al. Indoleamine 2,3-dioxygenase (IDO) in inflammation and allergy to Aspergillus. Med Mycol 2009; 47 Suppl 1: S154-61.
29. Stergiopoulou T, Meletiadis J, Roilides E, et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol. 2007; 127(3): 349-55.
30. Madan T, Kaur S, Saxena S, et al. Role of collectins in innate i mmunity against aspergillosis. Med Mycol 2005; 43 Suppl 1: S155-63.
31. Madan T, Reid KB, Singh M, Sarma PU, Kishore U. Susceptibility of mice genetically deficient in the surfactant protein (SP)-A or SPD gene to pulmonary hypersensitivity induced by antigens and allergens of Aspergillus fumigatus. J Immunol 2005; 174(11): 6943-54.
32. Pandit H, Madhukaran SP, Nayak A, Madan T. SP-A and SP-D in host defense against fungal infections and allergies. Front Biosci (Elite Ed) 2012; 4: 651-61.
33. Garlanda C, Hirsch E, Bozza S, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002; 420(6912): 182-6.
34. Werner JL, Metz AE, Horn D, et al. Requisite role for the dectin-1 beta-glucan receptor in pulmonary defense against Aspergillus fumigatus. J Immunol 2009; 182(8): 4938-46.
35. Latge JP, Mouyna I, Tekaia F, Beauvais A, Debeaupuis JP, Nierman W. Specific molecular features in the organization and biosynthesis of the cell wall of Aspergillus fumigatus. Med Mycol 2005; 43 Suppl 1: S15-22.
36. Aimanianda V, Bayry J, Bozza S, et al. Surface hydrophobin prevents immune recognition of airborne fungal spores. Nature 2009; 460(7259): 1117-21.
37. Cenci E, Perito S, Enssle KH, et al. Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun 1997; 65(2): 564-70.
38. Hartl D, Latzin P, Zissel G, Krane M, Krauss-Etschmann S, Griese M. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med 2006; 173(12): 1370-6.
39. Philippe B, Ibrahim-Granet O, Prevost MC, et al. Killing of Aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant intermediates. Infect Immun 2003; 71(6): 3034-42.
40. Bonnett CR, Cornish EJ, Harmsen AG, Burritt JB. Early neutrophil recruitment and aggregation in the murine lung inhibit germination of Aspergillus fumigatus Conidia. Infect Immun 2006; 74(12): 6528-39.
41. Zarember KA, Sugui JA, Chang YC, Kwon-Chung KJ, Gallin JI. Human polymorphonuclear leukocytes inhibit Aspergillus fumigatus conidial growth by lactoferrin-mediated iron depletion. J Immunol 2007; 178(10): 6367-73.
42. Montagnoli C, Fallarino F, Gaziano R, et al. Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. J Immunol 2006; 176(3): 1712-23.
43. Zelante T, De Luca A, Bonifazi P, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007; 37(10): 2695-706.
44. Romani L, Fallarino F, De Luca A, et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 2008; 451(7175): 211-5.
45. Geller DE, Kaplowitz H, Light MJ, Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Chest 1999; 116(3): 639-46.
46. Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 2000; 16(3): 464-71.
47. Paugam A, Baixench MT, Demazes-Dufeu N, et al. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol 2010; 48 Suppl 1: S32-6.
48. Ritz N, Ammann RA, Casaulta Aebischer C, Schoeni-Affolter F, Schoeni MH. Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis. Eur J Pediatr 2005; 164(9): 577-82.
49. Kraemer R, Delosea N, Ballinari P, Gallati S, Crameri R. Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2006; 174(11): 1211-20.
50. Jubin V, Ranque S, Stremler Le Bel N, Sarles J, Dubus JC. Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol 2010; 45(8): 764-71.
51. Bakare N, Rickerts V, Bargon J, Just-Nubling G. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 2003; 46(1-2): 19-23.
52. Chotirmall SH, O'Donoghue E, Bennett K, Gunaratnam C, O'Neill SJ, McElvaney NG. Sputum Candida albicans presages FEV(1) decline and hospital-treated exacerbations in cystic fibrosis. Chest 2010; 138(5): 1186-95.
53. Blyth CC, Middleton PG, Harun A, Sorrell TC, Meyer W, Chen SC. Clinical associations and prevalence of Scedosporium spp. in Australian cystic fibrosis patients: identification of novel risk factors? Med Mycol 2010; 48 Suppl 1: S37-44.
54. Cimon B, Carrere J, Vinatier JF, Chazalette JP, Chabasse D, Bouchara JP. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000; 19(1): 53-6.
55. Pihet M, Carrere J, Cimon B, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis--a review. Med Mycol 2009; 47(4): 387-97.
56. Delhaes L, Monchy S, Frealle E, et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community--implications for therapeutic management. PLoS One 2012; 7(4): e36313. Epub 2012Apr27
57. Zemanick ET, Sagel SD, Harris JK. The airway microbiome in cystic fibrosis and implications for treatment. Curr Opin Pediatr 2011; 23(3): 319-24.
58. Zhao J, Schloss PD, Kalikin LM, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci USA 2012 10; 109(15): 5809-14.
59. Hanley-Lopez J, Clement LT. Allergic bronchopulmonary aspergillosis in cystic fibrosis. Curr Opin Pulm Med 2000; 6(6): 540-4.
60. Knutsen AP, Slavin RG. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin Dev Immunol.2011: 843763.
61. Pashley CH, Fairs A, Morley JP, et al. Routine processing procedures for isolating filamentous fungi from respiratory sputum samples may underestimate fungal prevalence. Med Mycol 2012; 50(4): 433-8.
62. Moss RB. Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Curr Opin Pulm Med 2010; 16(6): 598-603.
63. Sudfeld CR, Dasenbrook EC, Merz WG, Carroll KC, Boyle MP. Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis. J Cyst Fibros 2010; 9(2): 110-6.
64. Nagano Y, Millar BC, Goldsmith CE, et al. Development of selective media for the isolation of yeasts and filamentous fungi from the sputum of adult patients with cystic fibrosis (CF). J Cyst Fibros 2008; 7(6): 566-72.
65. Nagano Y, Elborn JS, Millar BC, et al. Comparison of techniques to examine the diversity of fungi in adult patients with cystic fibrosis. Med Mycol 2010; 48(1): 166-76 e1.
66. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003; 2(1): 29-34.
67. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009; 135(3): 805-26.
68. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37 Suppl 3: S225-64.
69. Mroueh S, Spock A. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Chest 1994; 105(1): 32-6.
70. Nelson LA, Callerame ML, Schwartz RH. Aspergillosis and atopy in cystic fibrosis. Am Rev Respir Dis 1979; 120(4): 863-73.
71. Hafen GM, Hartl D, Regamey N, Casaulta C, Latzin P. Allergic bronchopulmonary aspergillosis: the hunt for a diagnostic serological marker in cystic fibrosis patients. Expert Rev Mol Diagn 2009; 9(2): 157-64.
72. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8(5): 349-61.
73. Eickmeier O, Hilberath JN, Zielen S, Haworth O. [Pro-resolving lipid mediators in inflammatory lung diseases]. Pneumologie 2011; 65(3): 149-58.
74. Cunningham S, Madge SL, Dinwiddie R. Survey of criteria used to diagnose allergic bronchopulmonary aspergillosis in cystic fibrosis. Arch Dis Child 2001; 84(1): 89.
75. Kanthan SK, Bush A, Kemp M, Buchdahl R. Factors effecting impact of Aspergillus fumigatus sensitization in cystic fibrosis. Pediatr Pulmonol 2007; 42(9): 785-93.
76. Tillie-Leblond I, Tonnel AB. Allergic bronchopulmonary aspergillosis. Allergy 2005; 60(8): 1004-13.
77. Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179(1): 11-8.
78. Feanny S, Forsyth S, Corey M, Levison H, Zimmerman B. Allergic bronchopulmonary aspergillosis in cystic fibrosis: a secretory immune response to a colonizing organism. Ann Allergy 1988; 60(1): 64-8.
79. Paul K, Rietschel E, Ballmann M, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004; 169(6): 719-25.
80. Shah PL, Scott SF, Knight RA, Hodson ME. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis. Eur Respir J 1996; 9(3): 531-4.
81. Hogaboam CM, Carpenter KJ, Schuh JM, Buckland KF. Aspergillus and asthma--any link? Med Mycol 2005; 43 Suppl 1: S197-202.
82. Islam SA, Luster AD. T cell homing to epithelial barriers in allergic disease. Nat Med 2012; 18(5): 705-15.
83. Barlow JL, McKenzie AN. Nuocytes: expanding the innate cell repertoire in type-2 immunity. J Leukoc Biol 2011; 90(5): 867-74.
84. Latzin P, Hartl D, Regamey N, Frey U, Schoeni MH, Casaulta C. Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J 2008; 31(1): 36-42.
85. Fujisawa T, Nagao M, Hiraguchi Y, et al. Serum measurement of thymus and activation-regulated chemokine/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and agespecific analysis in atopic dermatitis. Pediatr Allergy Immunol 2009; 20(7): 633-41.
86. Sekiya T, Tsunemi Y, Miyamasu M, et al. Variations in the human Th2-specific chemokine TARC gene. Immunogenetics 2003; 54(10): 742-5.
87. MacGlashan D, Jr. Expression of CD203c and CD63 in human basophils: relationship to differential regulation of piecemeal and anaphylactic degranulation processes. Clin Exp Allergy 2010; 40(9): 1365-77.
88. Ebo DG, Bridts CH, Hagendorens MM, Aerts NE, De Clerck LS, Stevens WJ. Basophil activation test by flow cytometry: present and future applications in allergology. Cytometry B Clin Cytom 2008; 74(4): 201-10.
89. Abuaf N, Rostane H, Rajoely B, et al. Comparison of two basophil activation markers CD63 and CD203c in the diagnosis of amoxicillin allergy. Clin Exp Allergy 2008; 38(6): 921-8.
90. Tokuda R, Nagao M, Hiraguchi Y, et al. Antigen-induced expression of CD203c on basophils predicts IgE-mediated wheat allergy. Allergol Int 2009; 58(2): 193-9.
91. Gernez Y, Dunn CE, Everson C, et al. Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens. J Cyst Fibros 2012 May 16.
92. Chaudhary N, Marr KA. Impact of Aspergillus fumigatus in allergic airway diseases. Clin Transl Allergy 2011; 10 (1): 4.
93. Greenberger PA. Allergic bronchopulmonary aspergillosis, allergic fungal sinusitis, and hypersensitivity pneumonitis. Clin Allergy Immunol 2002; 16: 449-68.
94. Patterson R, Greenberger PA, Radin RC, Roberts M. Allergic bronchopulmonary aspergillosis: staging as an aid to management. Ann Intern Med 1982; 96(3): 286-91.
95. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30(4): 696-709.
96. Capewell S, Chapman BJ, Alexander F, Greening AP, Crompton GK. Corticosteroid treatment and prognosis in pulmonary eosinophilia. Thorax 1989; 44(11): 925-9.
97. Thomson JM, Wesley A, Byrnes CA, Nixon GM. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol 2006; 41(2): 164-70.
98. Cohen-Cymberknoh M, Blau H, Shoseyov D, et al. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. J Cyst Fibros 2009; 8(4): 253-7.
99. Mussaffi H, Rivlin J, Shalit I, Ephros M, Blau H. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 2005; 25(2): 324-8.
100. Inhaled beclomethasone dipropionate in allergic bronchopulmonary aspergillosis. Report to the Research Committee of the British Thoracic Association. Br J Dis Chest 1979; 73(4): 349-56.
101. Heinig JH, Weeke ER, Groth S, Schwartz B. High-dose local steroid treatment in bronchopulmonary aspergillosis. A pilot study. Allergy 1988; 43(1): 24-31.
102. Ricketti AJ, Greenberger PA, Patterson R. Serum IgE as an important aid in management of allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1984; 74(1): 68-71.
103. Greenberger PA. Clinical aspects of allergic bronchopulmonary aspergillosis. Front Biosci. 2003; 8: s119-27.
104. Aaron SD, Vandemheen KL, Freitag A, et al. Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoS One 2012; 7(4): e36077.
105. Elphick HE, Southern KW. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev.6: CD002204.
106. Wark PA, Hensley MJ, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003; 111(5): 952-7.
107. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008; 21(6): 580-6.
108. Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN. Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother 2004; 38(1): 46-9.
109. Lestner JM, Roberts SA, Moore CB, Howard SJ, Denning DW, Hope WW. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009; 49(6): 928-30.
110. Hennig S, Waterhouse TH, Bell SC, et al. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Br J Clin Pharmacol 2007; 63(4): 438-50.
111. Glackin L, Leen G, Elnazir B, Greally P. Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Ir Med J 2009; 102(1): 29.
112. Patterson K, Strek ME. Allergic bronchopulmonary aspergillosis. Proc Am Thorac Soc. 2010; 7(3): 237-44.
113. Hilliard T, Edwards S, Buchdahl R, et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros 2005; 4(4): 215-20.
114. Pasqualotto AC, Shah M, Wynn R, Denning DW. Voriconazole plasma monitoring. Arch Dis Child 2008; 93(7): 578-81.
115. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46(2): 201-11.
116. Berge M, Guillemain R, Boussaud V, et al. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl Infect Dis 2009; 11(3): 211-9.
117. Howard SJ, Pasqualotto AC, Denning DW. Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect 2010; 16(6): 683-8.
118. Amorim A, Guedes-Vaz L, Araujo R. Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonised cystic fibrosis patients receiving azole therapy. Int J Antimicrob Agents 2010; 35(4): 396-9.
119. Burgel PR, Baixench MT, Amsellem M, et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother 2012; 56(2): 869-74.
120. Kuiper L, Ruijgrok EJ. A review on the clinical use of inhaled amphotericin B. J Aerosol Med Pulm Drug Deliv 2009; 22(3): 213-27.
121. Casey P, Garrett J, Eaton T. Allergic bronchopulmonary aspergillosis in a lung transplant patient successfully treated with nebulized amphotericin. J Heart Lung Transplant 2002; 21(11): 1237-41.
122. Hayes D, Jr., Murphy BS, Lynch JE, Feola DJ. Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis. Pediatr Pulmonol 2010; 45(11): 1145-8.
123. Laoudi Y, Paolini JB, Grimfed A, Just J. Nebulised corticosteroid and amphotericin B: an alternative treatment for ABPA? Eur Respir J 2008; 31(4): 908-9.
124. Proesmans M, Vermeulen F, Vreys M, De Boeck K. Use of nebulized amphotericin B in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Int J Pediatr 2010: 376287.
125. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 2008; 43(12): 1249-51.
126. Lebecque P, Leonard A, Argaz M, Godding V, Pilette C. Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. BMJ Case Rep 2009; 2009. pii: bcr07.2008.0379.
127. Lebecque P, Leonard A, Pilette C. Omalizumab for treatment of ABPA exacerbations in CF patients. Pediatr Pulmonol 2009; 44(5): 516.
128. Schulze J, Zissler U, Christmann M, Rosewich M, Zielen S. Allergic bronchopulmonary aspergillosis (ABPA) an IgE mediated disease? Respir Med 2010; 9: 33-4 Case Report.
129. van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62(3): 276-7.
130. Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008; 43(6): 607-10.
131. Brinkmann F, Schwerk N, Hansen G, Ballmann M. Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis. Allergy 2010; 65(1): 134-5.
132. Kreindler JL, Steele C, Nguyen N, et al. Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Clin Invest 2010; 120(9): 3242-54.